Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

Researchers have been "making great inroads" in precision medicine, and a 15 percent cap on indirect costs could quash the momentum, experts worry.

Barclays analyst Gena Wang raised the firm’s price target on Crispr Therapeutics (CRSP) to $56 from $55 and keeps an Equal Weight rating on the ...

CRISPR Therapeutics CRSP is expected to report fourth-quarter and full-year 2024 earnings later this month. The Zacks Consensus Estimate for quarterly sales is pegged at $10.13 million ...

Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR is hard to do profitably.

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against the other stocks in Cathie Wood’s portfolio. Cathie Wood is one of Wall Street’s most ...

I am Debjit, one of the therapeutic analysts here, and joining me from CRISPR Therapeutics is CEO, Samarth Kulkarni. Thank you so much, Sam. Yeah. Happy to do that. I think we’ve been around as ...